New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:16 EDTHZNPHorizon Pharma price target raised to $18 from $16 at JMP Securities
JMP Securities increased its price target on Horizon as the firm reports that the company's Vimovo drug is outpacing the firm's early expectations. The firm thinks the company could increase its 2014 guidance on its upcoming Q4 earnings call. JMP Securities expects the stock to rise following the earnings, and recommends owning the shares ahead of the results. It reiterates an Outperform rating on the shares.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
07:03 EDTHZNPHorizon Pharma announces USPTO issuance of Notice of Allowance
Subscribe for More Information
June 26, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $40 from $32 at UBS
Subscribe for More Information
June 23, 2015
07:36 EDTHZNPJMP Securities to hold a conference
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma announces notice of allowance with claims covering Ravicti
Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use